How AMC’s new subscription service stacks up to MoviePass and its competitors

This post was originally published on this site

Grab your popcorn because the battle of the movie-ticket subscription services is ratcheting up.

AMC AMC, +2.15% revealed Wednesday that it will begin offering its own movie-theater subscription service, to be called AMC Stubs A-List, later in June. The plan is designed to compete with MoviePass HMNY, -30.65% which has attracted notoriety since it lowered its subscription service’s monthly price to $9.95 a month last year.

This won’t be the first time that AMC and MoviePass have butt heads. Back in January, MoviePass removed some AMC theaters as an option for subscribers after the theater chain declined to enter into a partnership with those venues.

AMC has not made any moves to block competing services at its theaters, the company said. A spokeswoman for MoviePass said the company was “thrilled that AMC has finally stepped up to embrace a model that we’ve known all along will be the future of our industry.”

But MoviePass and AMC aren’t alone duking it out for moviegoers’ attention. Upstart movie ticket subscription service Sinemia, which was founded in Turkey in 2014, recently unveiled a new pricing plan in a bid to take on MoviePass.

Also see: Why the AT&T-Time Warner merger could be bad news for consumers

Sinemia Chief Executive Rifat Oguz welcomed the new competition, but remained skeptical of AMC’s approach. “AMC’s plan is trying to reach a niche segment of super moviegoers,” Oguz said in statement. “We have been an advocate of sustainable movie-ticket subscription offerings for the last 4 years, and when we look at the details of the AMC plan we fear that this will devalue the movie experience and simply is not sustainable.”

Last year, Texas-based movie theater chain Cinemark CNK, +1.25%  rolled out its own subscription service, called Movie Club.

Here’s how these subscription plans compare when it comes to price, benefits and other features:

AMC Stubs A-List: Great value, with a catch

For $19.95 a month (plus tax), A-List members can see three movies a week. Users can see more than one movie a day if they so choose (meaning double-features are a possibility) and see the same movie more than once. Users also can see any type of movie, including IMAX and 3D films, and purchase movie tickets in advance. Benefits reset every Friday, and members must commit to at least three months. Members do not receive a physical card, unlike with MoviePass and Sinemia.

As an upgraded version of the AMC Stubs Premiere loyalty program, A-List affords members all the same benefits including free refills on large popcorn, reward points for concessions purchases, free upgrades to popcorn and drink sizes and a birthday gift each year. A-List members also earn rewards points on their monthly membership fees, but don’t earn points for movie tickets they get through their membership.

Of course, there is one clear downside compared with MoviePass and Sinemia: A-List only works at AMC theaters. Also, there is no option to pay for a full year in advance, though the monthly price is guaranteed for 12 months once you sign up. Nevertheless, the AMC program represents a formidable competitor to MoviePass and Sinemia alike, particularly for those who live near an AMC location.

MoviePass: Unlimited movies

MoviePass has been around since 2011, but attracted major attention last August when it announced it would lower the price of its monthly subscription from $30 to just $9.95 a month.

The company has also offered different promotions to lure customers through partnerships with other companies. For instance, student-loan company Laurel Road recently began offering consumers a free year-long membership to MoviePass if they refinanced their loans with the company.

The standard $9.95 subscription entitles members to see one movie a day, every day, for the duration of their subscription. To see a movie, users select a participating theater within the MoviePass app and check in for a specific showtime of the film they want to see.

Doing that activates a debit card, which they use to purchase their ticket. MoviePass is accepted in more than 90% of U.S. theaters, but only in select theaters can subscribers purchase tickets in advance or online.

MoviePass also currently has a limited-time offer for a $7.95-a-month subscription that limits subscribers to three movies a month, but comes with a free three-month trial of iHeartRadio All-Access.

Since it ushered in the $9.95 price point, MoviePass has suffered some growing pains. Earlier this month, the company announced that it had surpassed 3 million subscribers. Before it lowered the price, the company had fewer than 150,000 subscribers.

Don’t miss: How NOT to bet during the World Cup, according to behavioral science

Amid that influx of new users, scores of customers complained that they never received their MoviePass cards in the mail or were unable to activate their cards in the app. Others argue the company abruptly canceled their subscriptions for no reason, though MoviePass argues they had violated its terms of service.

There are other catches to the service: Users can’t see the same movie twice, nor can they use MoviePass for 3D, Imax or other premium movie experiences.

And while some theaters allow e-ticketing with MoviePass, most subscribers must buy their tickets in person, which can make getting seats at popular movies more difficult. Additionally, the company does collect some data on users, raising privacy-related concerns.

Subscribers should also remain on the look-out for changes. MoviePass parent Helios and Matheson has struggled with cash flow issues and warned that if it didn’t obtain sufficient added capital it may need to alter its business model.

Nevertheless, MoviePass can be a great deal. For movie buffs who see multiple movies a month, the service can easily translate into hundreds of dollars in savings over a year.

Sinemia: Tiered pricing

Unlike MoviePass, Sinemia offers a tiered pricing model, with individual subscriptions currently ranging in price from $14.99 a month (for an Elite package that includes three movies a month including 3D films, IMAX movies and more) to $4.99 a month (for a Classic package that includes a single movie ticket to a 2D film.)

The company also has “Sinemia for Two” packages designed for couples that provide equivalent numbers of tickets for two people at each of the different tiers. These plans also come with deals at restaurants and partnerships with ride-share services, to complete the date experience.

Currently, the company offers an expensive unlimited movie plan in Europe, but has said it doesn’t plan to bring that to the U.S.

Sinemia works with most movie theaters and also allows subscribers to purchase movie tickets in advance and online. Sinemia also allows moviegoers to see the same film more than once. Like MoviePass though, users reserve movies in the app and pay in the theater with a Sinemia card.

It’s more expensive than MoviePass, but likely worth it for those who like to buy tickets ahead of time. It’s similarly a better deal for those who like to see the same movie more than once or go to major 3D blockbusters.

Read more: Is Amazon Prime worth its new $119 price tag?

Cinemark Movie Club: A limited option

The most bare-bones of all the subscription services, this program entitles members to one ticket to a 2D movie each month for a monthly fee of $8.99. After that, they can purchase two additional tickets at $8.99 each. However, the program also includes 20% off concessions, which can add additional savings.

If they are unused, the monthly credits roll over and are even redeemable for up to 6 months after a consumer chooses to cancel his or her membership. Credits are applied to members’ Cinemark accounts and can be redeemed in person, online or in the Cinemark mobile app.

And unlike other programs, Cinemark Movie Club members are not locked into a contract, meaning they can cancel at any time.

More from MarketWatch
Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.